Combined therapy in the treatment of hypertension

Fundamental and Clinical Pharmacology

Volumn 24, Issue 1, 2010, Pages 3-8

  Escobar, Carlos ^a   Barrios, Vivencio ^b  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Arterial hypertension; Calcium channel blockers; Combined therapy; Contact rates; Diuretics; Renin angiotensin system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; EUROPE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 74049096148     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00749.x     Document Type: Review

References (42)

1. Wang Y.R., Alexander G.C., Stafford R.S. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch. Intern. Med. (2007) 167 141 147.
2. Ong K.L., Cheung B.M., Man Y.B. et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension (2007) 49 69 75.
3. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. (2007) 25 1105 1187. (Pubitemid 46924065)
4. Barrios V., Banegas J.R., Ruilope L.M., Rodicio J.L. Evolution of blood pressure control in Spain. J. Hypertens. (2007) 25 1975 1977.
5. Barrios V., Escobar C., Calderón A. et al., CONTROLRISK Investigators Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J. Hum. Hypertens. (2007) 21 479 485.
6. Márquez-Contreras E., Coca A., de la Figuera M. et al. Cardiovascular risk profile of uncontrolled hypertensive patients. The Control-Project study. Med. Clin. (Barc). (2007) 128 86 91.
7. Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. (2007) 28 88 136.
8. Barrios V., Escobar C., Calderón A. et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J. Clin. Hypertens. (Greenwich). (2007) 9 324 329.
9. Barrios V., Escobar C., Calderón A. et al. Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis. J. Cardiometab. Syndr. (2007) 2 9 15.
10. Barrios V., Escobar C., Llisterri J.L. et al. Blood pressure and lipid control and coronary risk in the hypertensive population attended in Primary Care setting in Spain. The PRESCOT study. Rev. Clin. Esp. (2007) 207 172 178. (Pubitemid 46853769)
11. Motwani J.G. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J. Renin. Angiotensin. Aldosterone. Syst. (2002) 3 72 78.
12. Sica D.A. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs (2002) 62 44 62.
13. Coca A. Combination therapy under investigation in large-scale trials: The International Verapamil-Trandolapril Study (INVEST). J. Cardiovasc. Pharmacol. (1999) 34 (Suppl 3) s29 s35.
14. Lazarus J.M., Bourgoignie J.J., Buckalew V.M. et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The modification of diet in renal disease study group. Hypertension (1997) 29 641 650.
15. Estacio R.O., Schrier R.W. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am. J. Cardiol. (1998) 82 9R 14R.
16. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351 1755 1762. (Pubitemid 28269185)
17. Bakris G.L., Williams M., Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. (2000) 36 646 661.
18. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345 861 869. (Pubitemid 34940825)
19. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. (2001) 345 851 860.
20. UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 317 703 713.
21. Dahlöf B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366 895 906.
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack Trial (ALLHAT). JAMA (2002) 288 2981 2997.
23. Coca A. Blood pressure control among treated hypertensive patients by Primary Care in Spain. The 2003 Controlpres study. Hipertension (2005) 22 5 14.
24. Nesbitt S.D. Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction. J. Clin. Hypertens. (Greenwich). (2007) 9 (11 Suppl 4) 26 32.
25. Weir M.R., Levy D., Crikelair N., Rocha R., Meng X., Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am. J. Hypertens. (2007) 20 807 815.
26. McInnes G.T. Antihypertensive drugs in combination: additive or greater than additive? J. Hum. Hypertens. (2007) 21 914 916.
27. Barrios V., Escobar C., Echarri R. Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. Vasc. Health Risk Manag. (2008) 4 847 853.
28. Barrios V., Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin. Pharmacother. (2008) 9 129 136.
29. Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag. Care. (2000) 9 (9 Suppl) 2 6.
30. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. (2008) 358 1547 1559.
31. Solomon S.D, Appelbaum E., Manning W.J. et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation (2009) 119 530 537.
32. Fogari R., Corradi L., Zoppi A. et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am. J. Hypertens. (2007) 20 1092 1096.
33. Gojanovic B., Feihl F., Liaudet L. et al. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J. Renin. Angiotensin. Aldosterone. Syst. (2008) 9 1 9.
34. Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the elderly and lercanidipine (ELLE) study. Arch. Gerontol. Geriatr. (2003) 37 203 212.
35. Barrios V., Escobar C., de la Figuera M. et al. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. Int. J. Clin. Pract. (2008) 62 723 728.
36. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr. Cardiol. Reports (2002) 4 479 482.
37. Schrader J., Salvetti A., Calvo C. et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int. J. Clin. Pract. (2009) 63 217 225.
38. Weir M.R., Rosenberger C., Fink J.C. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am. J. Hypertens. (2001) 14 963 968.
39. Dahlöf B., Devereux R.B., Kjeldsen S.E. et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359 995 1003. (Pubitemid 34286536)
40. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al., INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA (2003) 3 290 2805 2816.
41. Ruggenenti P., Fassi A., Ilieva A.P. et al. Bergamo nephrologic diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. (2004) 351 1941 1951.
42. Jamerson K., Weber M.A., Bakris G.L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. (2008) 359 2417 2428.